Rates and Durability of Response to Salvage Radiation Therapy Among Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma

被引：2
|
作者：
Tseng, Y. D. [1 ]
Chen, Y. [2 ]
Catalano, P. [2 ]
Mauch, P. M. [3 ]
Ng, A. [3 ]
机构：
[1] Harvard Radiat Oncol Program, Boston, MA USA
[2] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2013年 / 87卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2013.06.156
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S60 / S60
页数：1
相关论文
共 50 条
  • [1] Rates and Durability of Response to Salvage Radiation Therapy Among Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma
    Tseng, Yolanda D.
    Chen, Yu-Hui
    Catalano, Paul J.
    Ng, Andrea
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 91 (01): : 223 - 231
  • [2] Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma
    Zlotnick, Maya
    Avigdor, Abraham
    Ribakovsky, Elena
    Nagler, Arnon
    Kedmi, Meirav
    ACTA HAEMATOLOGICA, 2019, 141 (02) : 84 - 90
  • [3] EFFICACY OF GEMCITABINE AS SALVAGE THERAPY FOR RELAPSED/REFRACTORY AGGRESSIVE NON HODGKIN LYMPHOMA PATIENTS
    Zlotnick, M.
    Avigdor, A.
    Ribakovsky, E.
    Nagler, A.
    Kedmi, M.
    HAEMATOLOGICA, 2016, 101 : 696 - 696
  • [4] FLUDAP: Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma
    Child, JA
    Johnson, SA
    Rule, S
    Smith, GM
    Morgan, GJ
    Johnson, PWM
    Prentice, AG
    Tollerfield, SM
    Wareham, E
    LEUKEMIA & LYMPHOMA, 2000, 37 (3-4) : 309 - 317
  • [5] ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma
    Choi, CW
    Paek, CW
    Seo, JH
    Kim, BS
    Shin, SW
    Kim, YH
    Kim, JS
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2002, 17 (05) : 621 - 624
  • [6] Outcome of Hodgkin's lymphoma and aggressive non-Hodgkin lymphoma patients refractory to salvage chemotherapy
    Castagna, L.
    Bramanti, S.
    Balzarotti, M.
    Giordano, L.
    Michieli, M.
    Anastasia, A.
    Magagnoli, M.
    Sarina, B.
    Todisco, E.
    Mazza, R.
    Nozza, A.
    Ibatici, A.
    Santoro, A.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S249 - S249
  • [7] Durability of complete response after blinatumomab therapy for refractory/relapsed aggressive B-cell non-Hodgkin lymphoma.
    Viardot, Andreas
    Hess, Georg
    Bargou, Ralf C.
    Morley, Nicholas
    Gritti, Giuseppe
    Iskander, Karim
    Cohan, David
    Zhang, Alicia
    Franklin, Janet
    Coyle, Luke
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Dexa-BEAM as salvage therapy in patients with primary refractory aggressive Non-Hodgkin lymphoma
    Atta, Johannes
    Chow, B-Ai U.
    Weidmann, Eckhart
    Mitrou, Paris S.
    Hoelzer, Dieter
    Martin, Hans
    LEUKEMIA & LYMPHOMA, 2007, 48 (02) : 349 - 356
  • [9] Ligustrazine as a salvage agent for patients with relapsed or refractory non-Hodgkin's lymphoma
    中华医学杂志(英文版), 2010, (22) : 3206 - 3211
  • [10] Ligustrazine as a salvage agent for patients with relapsed or refractory non-Hodgkin's lymphoma
    Yang Xi-gui
    Jiang Chao
    CHINESE MEDICAL JOURNAL, 2010, 123 (22) : 3206 - 3211
12345